Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply
- PMID: 34303433
- PMCID: PMC8298006
- DOI: 10.1016/S0140-6736(21)01422-7
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply
Conflict of interest statement
We declare no competing interests.
Comment on
-
Tocilizumab in COVID-19 therapy: who benefits, and how?Lancet. 2021 Jul 24;398(10297):299-300. doi: 10.1016/S0140-6736(21)01427-6. Lancet. 2021. PMID: 34303430 Free PMC article. No abstract available.
-
Tocilizumab in COVID-19 therapy: who benefits, and how?Lancet. 2021 Jul 24;398(10297):299. doi: 10.1016/S0140-6736(21)01380-5. Lancet. 2021. PMID: 34303431 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
